• Knightscope Inc. has seen a 46% drop in reported crime at one location and has operated over 1,000,000 hours of service for its autonomous security robots nationwide
• The versatility of the robots have seen their deployment in various areas such as airports, manufacturing plants, hospitals, stadiums, residential and commercial properties
• Recently, the Grand Sierra Resort and Casino adopted Knightscope’s K5 robot, aptly named “Jackbot,” to complement the facility’s existing security team
• This marks Knightscope’s growing client base that only confirms what the robots can do while working towards the company’s mission of a safer country

Knightscope’s mission, since its inception back in 2013, has been to make the United States of America the safest nation in the world while supporting millions of law enforcement and security professionals across the country. Driven by technology and innovation, the company has rolled out three products and overseen a 46% decrease in reported crime in one particular location and has operated well in excess of 1 million hours across the country. The company currently holds contracts across 6 U.S. time zones (https://ibn.fm/zKXC5). So far, Knightscope’s products operate in various areas of application including, but not limited to airports, manufacturing plants, hospitals, stadiums, residential and commercial properties, and numerous corporate campuses. In a client catalogue that seems to be steadily growing given the value proposition that Knightscope offers, the latest name therein has been the Grand Sierra Resort and Casino in Reno, Nevada (https://ibn.fm/qvloP). The resort features close to 2,000 hotel rooms and suites and a 100,000 square feet casino floor, the largest in northern Nevada (https://ibn.fm/yW2Ll). Additionally, it offers a broad range of dining, nightlife and entertainment options. Its move to adopt a Knightscope ASR to cover the massive facility is a testament to what Knightscope products can do, how dependable they are, and how much value they bring to the table. Knightscope is known for developing Autonomous Security Robot (“ASR”) products that feature self-driving technology, artificial intelligence (“AI”) and robotics. Its primary offerings are the K1 stationary machine, the K3 indoor machines and the K5 outdoor machine. All these products are developed from the ground up at Knightscope’s Mountain View, California facility. The Grand Sierra Resort and Casino went with the Knightscope K5 ASR that features two-way communication, 360-degree view cameras, an emergency call button and thermal imaging. Named “Jackbot,” this ASR is meant to work in tandem with the facility’s physical security team and add a layer of security to patrols within the space. It will serve as an extra set of eyes and ears and a much-needed added level of protection for the facility. There have been concerns regarding the safety of security jobs from automation, and with good reason. With innovations and offerings such as Knightscope’s K1, K3 and K5, it is easy for one to see how, ultimately, they could take over all security jobs. That is, however, not the case. In an interview with Knightscope’s CEO, William Santana Li, he noted that “The robots are intended to be eyes and ears for the humans, not a one to one replacement (https://ibn.fm/Elwaj).” This is further affirmed by the Grand Sierra Resort and Casino’s adoption and use of the robots for its security needs. The facility’s K5 “Jackbot” is meant to allow officers to see and hear what is going on, communicate with staff and customers through the robot and, when needed, dispatch additional officers. Jackbot is not a replacement but rather a tool that complements the facility’s security personnel, just as Knightscope intended it to be. As Knightscope’s ASRs continue to log more hours in the field, more data is being collected, facilitating the further improvement of the robots and the value they offer. In addition, establishments such as the Grand Sierra Resort and Casino see the value of the robots, consequently integrating them into their spaces. As such, it is only a matter of time before they become more mainstream, get to serve in more diverse areas and contribute to Knightscope Inc.’s mission of making the United States of America the safest nation in the world. For more information, visit the company’s website at www.Knightscope.com and if you have a need for subscription service you may request a private demonstration of the technology at www.Knightscope.com/demo. NOTE TO INVESTORS: The latest news and updates relating to Knightscope are available in the company’s newsroom at https://ibn.fm/Knight

• Brain cancer drug developer CNS Pharmaceuticals is actively enrolling patients for a potentially pivotal Phase 2 trial of the company’s lead drug candidate, Berubicin, a promising candidate for treating a devastating condition
• CNS’s focus has been on developing a means of combating glioblastoma, a fatal, generally incurable class of brain cancers that are aggressive and recurrent amid current surgical and chemotherapy interventions
• One patient from the Phase 1 trial of Berubicin 15 years ago remains cancer-free, as assessed in November, despite glioblastoma’s reputation for proving fatal generally within about 15 months of diagnosis
• CNS recently announced it will be included in the Russell 2000 Index of small-cap companies for the coming year, effective June 25, which it expects to boost its visibility among investors

As novel biopharmaceutical CNS Pharmaceuticals (NASDAQ: CNSP) approaches its annual meeting of stockholders scheduled for June 28, the company is enthusiastically pursuing enrollment of about 243 brain cancer patients in a clinical trial designed to analyze the efficacy and safety of the company’s lead drug candidate. The Phase 2 trial will compare the drug Berubicin’s response to established chemotherapy drug lomustine in treating glioblastoma (“GBM”), a fatal class of brain cancers generally considered incurable which usually only leaves patients about 15 months to live on average once they are diagnosed. Patient enrollment began last month across 35 clinical sites in the United States and CNS expects to expand the trial into western Europe during the coming year (https://ibn.fm/KEVIq). Once about 30 to 50 percent of the patients have reached the six-month point in the trial, CNS will conduct an interim non-binding futility analysis to obtain a snapshot of safety and secondary efficacy outcomes while enrollment otherwise continues. Berubicin, an anthracycline chemotherapy agent believed to be the first to successfully cross the blood-brain barrier to improve treatment capability, was the subject of a Phase 1 trial 15 years ago that resulted in the long-term survivability of one patient who achieved cancer-free status and continued in that condition during the most recent evaluation conducted in November. Among the other small pool of patients participating at that time, 44 percent saw their disease stabilize or improve, generating optimism for the drug’s potential (https://ibn.fm/gQBzo). CNS’s efforts have generated interest in the investment community that resulted in the company’s selection to be added to the Russell 2000 Index effective June 25, when the index undergoes its annual reconstitution, according to a news release announcement June 17 (https://ibn.fm/Pj9pQ). The reconstitution draws in the largest U.S. stocks each year and provides a benchmark measure consulted by investment managers and institutional investors for active investment strategies. The Russell 2000 Index is a measure of the performance of the small-cap segment of the U.S. equity market, a subset of the Russell 3000 Index that represents about 10 percent of the total market capitalization of that index, according to the announcement. “We are pleased to meet this noteworthy milestone and be included in the Russell 2000 Index. As our team continues to drive our clinical program forward for the treatment of glioblastoma multiforme (GBM), we believe this inclusion well-positions us to drive market awareness,” CNS Pharmaceuticals CEO John Climaco stated. “We are honored to be listed among our industry peers on what is considered to be a widely respected performance benchmark for small-cap companies. We look forward to leveraging the access and positioning this inclusion brings to unlock additional value.” CNS has sublicensed Berubicin to Polish company WPD Pharmaceuticals, which will commence a similar Phase 2 clinical trial in Europe during 2H 2021. WPD also plans to conduct a clinical trial examining Berubicin’s safety for pediatric malignant glioma patients later in the year, which would be the first significant investigation of the therapy in these brain cancers in children (https://ibn.fm/VEY0J). WPD is also helping to advance GBM research by participating in an international consortium of industry experts researching the potential of nanoparticles in maximizing the efficiency of radiotherapy in X-ray dosing to end the recurrence of these high-grade tumors while preserving the adjacent healthy tissue (https://ibn.fm/p7Ydz). For more information, visit the company’s website at www.CNSPharma.com. NOTE TO INVESTORS: The latest news and updates relating to CNSP are available in the company’s newsroom at https://ibn.fm/CNSP

• The agricultural produce treatment space has been active in recent years, attracting more than $26 billion in new investment in 2020
• In May 2021, Save Foods Inc. closed on a $12 million public offering and uplisted its shares to the Nasdaq
• The company has seen rapid movement from successful pilots with packing houses and food retailers
• Save Foods Inc. products present prospective competitors multiple barriers to entry, including a short time to market, zero toxic residues and addressing both spoilage and food safety
• The company has an exclusive agreement with PlanetAgro for distribution of Save Foods’ products in Mexico

Save Foods (NASDAQ: SVFD) is an agri-food tech company focused on developing and selling eco-friendly products specifically designed to ensure food safety and extend the shelf life of fresh fruits and vegetables. The company is focused on addressing two of the most significant challenges faced by the industry: (1) food waste and loss, and (2) food safety. Fungi like mold and yeast, as well as foodborne pathogens, are typically responsible for fresh produce spoilage and foodborne illness. Save Foods’ integrated solutions improve safety, freshness and quality every step of the way, from field to fork. The company’s natural products control human and plant pathogens, allowing growers, packers and food retailers to reduce waste and boost revenues. More food ends up on consumers’ plates, and less ends up in landfills. Save Foods’ products use all-natural ingredients to protect fresh produce from microbial spoilage and pathogens with zero toxicity. The company’s treatments leave no harmful residues on produce or in the environment and maintain product freshness over time. Fresh produce treated with Save Foods’ products can already be found in supermarket chains across the U.S. and Europe. Those chains have reported that the company’s products are reducing fruit spoilage by 50% on average at the retail level. With no need for additional steps in the treatment process nor special equipment, Save Foods’ products are easy to implement and come in versatile applications suitable for the different stakeholders along the food supply chain. Initial applications for the company’s offerings include post-harvest treatments in fruit and vegetable packing houses that process citrus, avocados, pears, bell peppers and mangos. By controlling and preventing pathogen contamination and significantly reducing the use of chemicals and their residues, Save Foods’ products not only prolong shelf life; they also ensure safe, natural and healthy food. Save Foods has the first green products that could realistically replace the different chemicals used today in food treatment while controlling waste and food safety. Products & Technology

• SavePROTECT or PeroStar, a processing aid added to fruit and vegetable wash water and used in post-harvest treatment;
• SF3HS and SF3H, post-harvest treartment solutions to control both plant and foodborne pathogens;
• SpuDefender, for controlling post-harvest potato sprouts; and
• FreshPROTECT, for controlling spoilage microorganisms on post-harvest citrus.

Save Foods’ products are based on a proprietary blend of food acids which have a synergistic effect when combined with certain types of sanitizers and fungicides at low concentrations in a non-organic setting. The combination eliminates fungicide residues or reduces them to levels below the established Maximum Residue Levels (“MRLs”). The company’s fruit and vegetable wash is odorless and does not irritate human eyes, skin or airways. Save Foods’ blend does not leave any residues of toxicological concern on the treated surface of produce, and all its ingredients are classified by the U.S. Food and Drug Administration (“FDA”) as Generally Recognized As Safe (“GRAS”). There are 7 patent families related to Save Foods’ technology. Applications The company’s products have been commercially validated on citrus, mangos, avocados, pears, bell peppers, microgreens and various fresh cut vegetables. Save Foods is in the validation process for bananas, apples, figs, berries, lettuce, papayas and more. The company is also validating the efficacy of its products for pre-harvest treatment, starting with citrus trees. Market Outlook The world population is expected to grow to almost 10 billion by 2050, boosting current agricultural demand by some 50%. Providing healthy and safe food for the world’s population is one of the biggest challenges of the 21st century. Globally, around 664 million tons of fresh fruits and vegetables are lost every year from field to fork, wasted by spoilage, and almost one in 10 people globally falls ill every year from eating contaminated food, with an estimated resulting cost around $90 billion. Disposing of all that wasted food requires additional expense and harms the environment with resulting greenhouse gas emissions. The post-harvest food treatment market was valued at $1.5 billion in 2019 and is expected to grow to $2.3 billion by 2026, achieving a CAGR of 6.5%. Management Team David Palach is CEO of Save Foods. He spent over a decade with Intel Israel, where his last position was Manager of Business Development for Israel and Europe. Prior to that, he served as a controller of two of Intel’s largest factories in Israel, where he supervised a budget of over $1 billion. He also served as the CEO of B-Pure Corporation Ltd., a management and maintenance company involved in protecting and improving the environment. During his tenure, he helped turn around several struggling subsidiaries and made them profitable. Vered Raz Avayo is the company’s CFO. Before joining SaveFoods in 2018, she spent more than 10 years as CFO at LGC, the Leviev Group of Companies. She has operated her own financial and business consultancy and has served as a director for a number of public companies in Israel. Dan Sztybel is CEO of SaveFoods Ltd., the Israeli subsidiary of Save Foods Inc. He previously led the Life Sciences Advisory at EY Israel and early on recognized the potential of Israel as a center of innovation in the digital health space. He has been an adviser on digital health strategy to large pharmaceutical companies and is a cofounder of MyndYou, a digital health start-up focusing on cognitive impairment. He is also a co-founder of the DigitalHealth.il conference, the largest digital health conference in Israel. Dr. Neta Matis is Vice President of R&D at Save Foods Ltd the Israeli subsidiary of Save Foods Inc . She holds a Ph.D. in organic chemistry and an MBA from Tel Aviv University. Prior to joining Save Foods in 2019, she held multiple research chemist and product development roles at Verdia Inc. and its parent company, Helsinki-based Stora Enso Oyj. Nimrod Ben Yehuda is the founder and CTO of Save Foods Ltd. He was previously the CEO/CTO of Swissteril Water Purifications Ltd. He has also been CEO at Nir Ecology Ltd., and was Joint-CEO at NitroJet Ltd. Dr. Art Dawson is the U.S. Business Manager for SaveFoods Inc. He has been president of The Dawson Company, which focuses on creating sales opportunities for new agricultural technologies, previously Dr. Dawson held senior industry positions like General Manager Worldwide of the Decco, the Post Harvest Division for Elf Atochem. He holds a Ph.D. in Plant Physiology from UC Riverside and is licensed in California as an agricultural Pest Control Advisor. For more information, visit the company’s website at www.SaveFoods.co. NOTE TO INVESTORS: The latest news and updates relating to SVFD are available in the company’s newsroom at https://ibn.fm/SVFD

• The company has developed and brought to market a pediatric NeuroCap
• EEG testing in pediatrics may help diagnose autism, one of the fastest-growing developmental disorders in the US, and provide better treatment for pediatric patients with epilepsy
• COVID-19 made the process challenging but the team completed their task on time despite no in-person contact and the process coming to a halt twice due to shutdowns

Brain Scientific (OTCQB: BRSF), a health care company on a mission to modernize brain diagnostics with cutting-edge technologies, has developed and brought to market a pediatric-specific disposable EEG cap. The pediatric NeuroCap may aid in diagnosing autism and providing much needed information in treating pediatric epilepsy. Autism is difficult to diagnose, yet the earlier it is discovered, the better the possibility of preventing some of the behaviors. A study published in the Scientific Reports Journal stated that EEGs can be used to accurately predict or rule out autism in children as young as three months (https://ibn.fm/t3KJq). One in fifty-nine children is diagnosed with autism by the time they are eight years old. It is one of the fastest-growing developmental disorders in the US, and the lifetime costs range anywhere from $1.4 to $2.2 million. (https://ibn.fm/XTPYG). The CDC reports that there are approximately 470,000 children in the US with active epilepsy (https://ibn.fm/bs0Cv). Epilepsy does not present itself the same in every patient because there are many causes as well as many different types of seizures. This can make diagnosis challenging and EEGs are used in a supportive role combined with history, examinations and other tests (https://ibn.fm/Ja4Si). When diagnosing children, the challenge comes in using ill-fitting bulky medical equipment designed for adults. The supply and availability of EEG testing in pediatrics are simply limited. Or it was until Brain Scientific decided to fill the gap and make easy-to-use disposable headsets for children and teens. According to an article in Today’s Medical Developments (https://ibn.fm/CniU1),  the team first approached the task intending to take the existing NeuroCap shrink it down to fit children and teens while also shortening the testing time from 30 minutes to 10 minutes. The process proved more challenging than expected in large part due to the pandemic. Unable to meet in person, the team brainstormed through video conferencing and provided manufacturing instructions in pain-stacking detail. The manufacturer and one of the suppliers were forced to shut down at different times, both of which brought the process to a temporary halt. Still, the team pushed forward, ensuring the timing was right, and they were the first to bring this product to the market. BRSF achieved the goal of creating a comfortable design in miniature and faster test results making the NeuroCap the perfect solution for pediatrics. For more information, visit the company’s website at www.BrainScientific.com/Invest-Now. NOTE TO INVESTORS: The latest news and updates relating to BRSF are available in the company’s newsroom at https://ibn.fm/BRSF

• Recent agreements have been strategic steps taken by BEV to position itself in growing U.S. market
• Agreements involve key manufacturing, distribution, fulfillment partners
• TRACE products feature the company’s alkaline, plant-based mineral beverages and nutraceuticals

Committed to creating a powerful ecosystem focused on developing and manufacturing alkaline, plant-based, and cannabinoid beverages and supplements, BevCanna Enterprises (CSE: BEV) (OTCQB: BVNNF) (FSE: 7BC) has announced a number of agreements recently. Each agreement has been part of a strategic business plan as the company moves into the United States and strengthens its position as a leading resource of high-quality health and wellness beverages and natural products for both in-house brands as well as white-label clients. In May, BevCanna finalized a co-packing agreement with California-based Riviera Beverages LLC (https://ibn.fm/0cUSX). The agreement outlines arrangements for Riviera to manufacture BevCanna’s TRACE plant-based and hemp-derived CBD bottled beverages for both its U.S. and international markets. “This agreement with Riviera is a significant step forward in our strategy to penetrate the U.S. and international markets with our TRACE plant-based mineral, and hemp-derived CBD-infused beverages,” said BevCanna president Melise Panetta. “We’ve been actively seeking U.S. and international growth opportunities for this portfolio, and Riviera is an ideal partner to advance this strategy. Their expertise and capacity to produce high-quality bottled beverages is an excellent fit for us.” A few days later, BevCanna announced a partnership with Benefit Brand Management, a leading U.S. wholesaler of natural products, to expand distribution of TRACE products (https://ibn.fm/TmcCB). BevCanna’s contract with Benefit calls for Benefit to distribute the exclusive products to a wide range of U.S. retailers, from independent natural and specialty retailers to national big box retailers. “With demand for wellness-focused beverages rapidly increasing among U.S. consumers, this is the ideal time to introduce the TRACE brand to a whole new demographic,” said Panetta. “We’re very excited to work with Benefit on launching the brand, capitalizing on their extensive network and detailed knowledge of the natural products retail landscape in the U.S.” Finally, on May 28, BevCanna inked a deal with a leading U.S. inventory and fulfillment technology platform provider (https://ibn.fm/y25wJ). Named by “Fast Company” magazine as one of the world’s most innovative companies, the tech provider offers a flexible, reliable fulfillment platform that uses cloud-based logistics to help businesses manage and fulfil inventory. “We’re pleased to be able to leverage this unique logistics systems in the U.S. launch of our TRACE line of products,” said Panetta. “Employing this sophisticated cloud-based platform will allow us to accelerate our launch across the country and ensure seamless delivery of our TRACE products to retailers nation-wide.” BevCanna’s suite of TRACE brand features the company’s plant-based mineral beverages and nutraceuticals; the line includes RTD beverages, shots, and mineral concentrate, along with new products under development. BevCanna announced its anticipated launch line in the United States in early May (https://ibn.fm/2JJym). Each of TRACE’s plant-based products include a proprietary fulvic and humic mineral formula, sourced from ancient organic compounds, which are highly concentrated sources of trace minerals. Recognized benefits of the Health Canada-approved formulations include improvements to cognitive performance, gut health and immune function, and stimulating the body to better metabolize carbohydrates, fats and proteins. BevCanna Enterprises is a diversified health & wellness beverage and natural products company focused on developing and manufacturing a range of alkaline, plant-based, and cannabinoid beverages and supplements for both in-house brands and white-label clients. The BevCanna team boasts decades of experience creating, manufacturing and distributing iconic brands that resonate with consumers on a global scale. For more information, visit the company’s website at www.BevCanna.com. NOTE TO INVESTORS: The latest news and updates relating to BVNNF are available in the company’s newsroom at http://ibn.fm/BVNNF

June 22-24, 2021 Virtual Event The 6th Annual Medical Device Human Factors & Usability Conference will be held from June 22-24, 2021, at the Q1 Productions dynamic virtual platform. Companies, representatives, and professionals from the Medical Device, Diagnostic and Combination products industry are invited to attend this virtual event. Operating since 2006, Q1 Productions specializes in delivering educational programming through its curated conferences and research-based events. The programs conducted in Q1 Production conferences are focused and learning is achieved through fun and interactive sessions. The sponsors of the event are:

• BlackHägen Design is a multidisciplinary, user-research, and product development firm.
• UserWise is a Human Factors Engineers’ firm designing best-in-class medical products, packaging, and labeling.
• CPC (Colder Products Company) focuses on designing and developing quick disconnect couplings, fittings, and connectors.
• Agilis is a Human Factors strategy consultancy for the global medical market.

Influential speakers like regulatory authorities and medical device peers will grace the event to share their opinions, keynotes and discuss the new FDA requirements and suggest practical testing roadmaps to understand the user needs and their successful transformation into designs. This Q1 platform offers a wonderful collaboration opportunity for participants who will get unique perspectives and learn innovative strategies for improved usability and product safety. The conference agenda is divided into 3 Modules distributed equally over three days. Participants can log in with a zoom sign-in and avail access to all the aspects of the 3-day conference. Some important topics of discussion at the conference are:

• The recent amendments to IEC-62366 and their impact on the usability process
• A breakdown of the future use, conceptualization, and evolution of task analysis
• The usability engineering regulatory landscape
• Awareness and insights into regulatory requirements during pandemic times
• Optimizing key environmental factors
• All aspects of improving usability to ensure product success

The Q1 app is available on mobile and offers onsite networking for users to stay connected.  The Virtual Event Guide & FAQ  offers insight into the dynamic Q1 event platform, offering additional features that will prove useful to the users. The 6th Annual Medical Device Human Factors & Usability Conference will offer a complete Medical Device Human Factors learning guide for startups and established companies in the medical device and diagnostic segment. For more details regarding the event, please visit https://ibn.fm/kK0AG

• Company’s i/Blue Imaging System(TM) is expected to be completed in 2022
• The American Cancer Society estimates that 2021 will see 83,370 new cases of bladder cancer and approximately 17,200 deaths
• More than half of the patients who underwent a cystoscopy to remove non-muscle-invasive bladder cancer will experience recurrence
• The bladder cancer market was valued at $3.43 billion in 2020, and is anticipated to reach $4.71 billion by 2028

According to the American Cancer Society, new cases of bladder cancer in the United States are expected to reach 83,730 in 2021 and deaths are anticipated to reach 17,200 (https://ibn.fm/zNRWl). Approximately 50% of patients who have had minimally invasive surgery to remove non-muscle-invasive bladder cancer will see their cancer return (https://ibn.fm/cdSKN). Scientists’ current areas of focus include the identification and causes/predictors of recurrence, as bladder cancer remains not only one of the most prevalent forms of cancer, but also one with a very high recurrence rate. To potentially help lower this high recurrence rate, surgical imaging company Imagin Medical (CSE: IME) (OTCQB: IMEXF) is finalizing the design-for-manufacturing of the i/Blue Imaging System, an innovative technology designed to significantly improve surgeons’ ability to visualize cancerous cells and enable more accurate bladder cancer resection. The company’s patented technology will display blue and white light images of the bladder side-by-side simultaneously, providing surgeons better visualization to remove cancer. White light cystoscopy is still the industry standard in over 90% of the procedures performed. The largest drawback with white light is that only the cancerous tumors that protrude from the bladder wall are easily identified. Using only white light, it is almost impossible to differentiate flat tumors from regular tissue and create clean margins, which means cancerous cells might be left behind and cause recurrence. Blue light cystoscopy (“BLC”) addresses this challenge by using a contrast agent that fluoresces the cancerous cells, both those along the margins and flat tumors, a vast improvement over white light cystoscopy. By enhancing visualization for the surgeon, BLC has been proven to detect 25% more cancerous tumors. However, resection cannot be completed using blue light images alone. Surgeons use the blue light image to see the cancer but need the white light image to determine the position within the bladder, requiring them to switch back and forth between the white light and blue light images and rely on memory to resect. Imagin Medical’s i/Blue Imaging System will help overcome this and other challenges. The company’s advanced technology will show both images simultaneously side-by-side on one screen, providing surgeons with better visualization to remove the cancer and making procedures more efficient. Imagin Medical’s technology is currently in the manufacturing stage with Lighthouse Imaging, an FDA-registered and ISO 13485:2016 certified manufacturer. The i/Blue Imaging System is expected to be completed in 2022. The technology fits most existing endoscopes on the market, allowing medical facilities to continue using scopes they already have without costly equipment investments. This feature allows hospitals and physicians to provide their patients with the latest technology at a lower cost, making potential widespread adoption easier. Leveraging this innovative technology, Imagin Medical is uniquely positioned to disrupt the bladder cancer market. The global bladder cancer therapeutics market was valued at $3.43 billion in 2020 and is expected to grow at a CAGR of 4.03% from 2021 to 2028, to reach $4.71 billion by 2028. Factors affecting this are the escalation of bladder cancer, increased awareness of available therapies, growing healthcare expenditure, and more (https://ibn.fm/p0jei). Although Imagin Medical is currently focused on bladder cancer, the company intends to expand its technology to other types of minimally invasive surgery in the future, such as laparoscopic, and accommodate multiple fluorescing imaging agents such as hexaminolevulinate (“HLA”) and Indocyanine green (“ICG”). For more information, visit the company’s website at www.ImaginMedical.com. NOTE TO INVESTORS: The latest news and updates relating to IMEXF are available in the company’s newsroom at https://ibn.fm/IMEXF

• Company expects reporting on interim analysis for the first 18 patients of a Phase 2 multicenter clinical trial of Berubicin in adult GBM patients during the first half of 2022
• One patient from the first Berubicin trial has survived cancer-free for 14 years, while two patients saw tumor reduction of up to 80 percent
• CNS Pharmaceuticals reported a net loss of $3.6 million, attributed to increased personnel, activity preparing for clinical trials, drug manufacturing, and labor for the Phase 2 study
• The global brain tumor therapeutics market is expected to grow at a CAGR during 2020-2025, resulting in forecasted market size of $1.6 billion by 2025

CNS Pharmaceuticals (NASDAQ: CNSP), a developer of novel treatments for primary and metastatic cancers of the brain and central nervous system, recently reported the summary of financial results for the first quarter of 2021. For the period ending March 2021, CNS reported research and development expenses in excess of $2.2 million, compared to $0.6 million for the same period in 2020 (https://ibn.fm/6GRIf). The expenses incurred are due to the drug manufacturing and labor related to the preparation for the Phase 2 study. An approximate total of $1.4 million was spent on general and administrative expenses, which is in line with the $1.3 million spent during the same period in 2020. The company reported that the three months ending March 2021 resulted in a net loss of approximately $3.6 million compared to the approximately $2.0 million for the comparable period in 2020. CNS attributes the net loss to increased personnel and activity associated with preparing for the company’s clinical trials in 2020. Berubicin, CNS’s lead drug candidate, is a novel anthracycline and the first anthracycline to appear to cross the blood-brain barrier based on limited clinical data. The company is currently developing Berubicin to be used to treat several serious brain and central nervous system oncological indications and plans to commence patient enrollment in a potentially pivotal study to evaluate the efficacy of Berubicin for adult Glioblastoma Multiforme (“GBM”) in the second quarter. Additionally, the company’s sublicensee partner in Poland, WPD Pharmaceuticals, will initiate a Phase 2 multicenter clinical trial of Berubicin in adult GBM patients in the second half of 2021, and is expected to report an interim analysis of the first 18 patients during the first half of 2022.WPD Pharmaceuticals is also scheduled to launch the first-ever Phase 1 pediatric trial for Berubicin, sometime during H2 2021. The first clinical trials of Berubicin were completed in 2006 by Reata Pharmaceuticals Inc. Since then, one of the original patients from the trial has survived 14 years cancer-free, while two additional participants saw tumor reduction of up to 80 percent. At this time, the Food and Drug Administration (“FDA”) has granted Orphan Drug Designation to Berubicin, providing CNS seven years of marketing exclusivity upon approval of an NDA. CNS intends to file for additional patents on Berubicin to further secure intellectual property. CNS CEO John Climaco underlined that 2021 is poised to be an exciting year for the company. “Throughout the first quarter, we have made continued development and regulatory progress on all fronts. We are committed to driving our novel treatments forward as expeditiously as possible with the primary focus on our Berubicin program to improve patient outcomes for GBM,” Climaco said. Despite the progress being made in surgical procedures and other therapies, effective treatments for brain tumors are limited by the lack of specific therapies for the brain. A significant amount of these setbacks has to do with the inability to cross the blood-brain barrier. Berubicin is the first to be able to accomplish this task, enabling CNS Pharmaceuticals to secure a unique position on the expanding brain tumor therapeutics market. The global brain tumor therapeutics sector was valued at $1.1 billion in 2019, and is expected to grow at a CAGR of 10%, reaching a total of $1.6 billion by 2025 (https://ibn.fm/9DYsF). For more information, visit the company’s website at www.CNSPharma.com. NOTE TO INVESTORS: The latest news and updates relating to CNSP are available in the company’s newsroom at https://ibn.fm/CNSP

• AI solutions company Infobird has announced an agreement to provide e-commerce platform upgrades for elderly consumer footwear manufacturing giant Zu Li Jian
• The Beijing-based company delivers intelligent B2B services, and the Zu Li Jian agreement demonstrates the growing integration of online consumers among a population more inclined to use traditional market channels
• Infobird also recently announced an agreement to provide its web-based optimization services to cosmetics retailer SaSa Cosmetics (China)
• The company has 70 proprietary licensing rights developed under its cloud computing structure and AI technologies, and recently completed its launch on the Nasdaq Capital Market

A month after SaaS innovator Infobird (NASDAQ: IFBD) made its Nasdaq debut, the artificial intelligence  (“AI”) solutions company focused on commerce in China, has begun building new retail agreements that promise to draw more attention to Infobird’s digital customer engagement solutions for improvements to customer service, management, and marketing. The Beijing, China-based company announced June 10 that its platform will provide Zu Li Jian, a pioneer in the production of footwear for the elderly in China, with cloud-native, autonomous, and controllable source code resources, to create flexible customization and expansion for Zu Li Jian’s own e-shopping platform. Infobird’s upgrade will grant Zu Li Jean’s customer service platform high stability, high concurrency and high expansion capability, according to the announcement, making it responsive to future needs and business peaks (https://ibn.fm/9AE2w). The announcement follows on the heels of a similar intelligent B2B collaboration that will deliver enhanced customer service and marketing capabilities to beauty retail services company SaSa Cosmetics (China) Co., Ltd. (https://ibn.fm/6qBWs). Together, these latest agreements provide validation that Infobird’s SaaS products have successfully entered the retail industry and are gaining recognition from reputable large enterprises. Zu Li Jian has more than 2,000 specialty stores nationwide and has successively obtained 245 patents for utility models and appearance designs of elderly footwear. The company has become a world-scale provider of consumer products for the elderly by developing footwear and clothing, daily necessities and technology products. Zu Li Jian’s e-commerce portal has achieved full-channel coverage and provides evidence that China’s elderly population — reported at more than 260 million people over the age of 60 — is gradually adopting Internet technology’s consumption and interaction channels into their daily lives. Infobird’s solutions also help clients to improve their performance efficiency through analysis of big data, using AI capabilities to better identify and understand their customers, markets and products in order to create a foundation for precision marketing. Infobird is undergoing a strategic transformation, making its product evolve from customized SaaS to standardized SaaS. In the process, Infobird’s client base is growing more diversified to cover more industry sectors. The company predicts its revenue will grow more than 50 percent during fiscal 2021 to between $22 million and $25 million. Infobird also has significant experience in the finance industry that it expects to leverage as it attempts to grow into other industries. For more information, visit the company’s website at www.Infobird.com/en/index.html. NOTE TO INVESTORS: The latest news and updates relating to IFBD are available in the company’s newsroom at https://ibn.fm/IFBD

• The first shipment of SMART inhalers, 10,000 cartridges and QR codes arrived in the UK for the clinic’s pilot run
• Due to the large scale of the clinical trial, RYAH developed a custom software solution for the clinic
• In the UK the medical cannabis market is expected to reach $1.3 billion by 2024, and 1% of the population could be medical cannabis patients by 2028

RYAH Group (CSE: RYAH), a connected device and big data and technology company, has completed its initial shipment to a major international clinic conducting a study in the UK on the safety and efficacy of cannabis and hemp for the treatment of chronic pain (https://ibn.fm/ZAJ0b). The first shipment will be used by the clinic in a pilot run. It consisted of RYAH’s Smart Dry Herb Inhalers, including 10,000 RYAH Cartridges and QR Codes. The complete order estimated to be tens of thousands of dry herb vaporizers and several million RYAH proprietary dry herb cartridges, to be purchased over five years (https://ibn.fm/RJncA). This study is one of the world’s largest and most comprehensive clinical trials in plant-based medicine. When the purchase order was first announced, Jordan Medley, Director of Product Operations at RYAH stated, “We are thrilled to create a custom solution for our clinic partner that helps facilitate the unique needs of their study. By giving the clinic the ability to a) prescribe a specific amount of dry herb medicine in pre-filled, tamper proof cartridges, and b) set a specific temperature and dose for each of their patients in their very own app, it improves the integrity of the study by removing key variables that could drastically influence the effects that their patients experience.” Due to the large scale of the study, RYAH developed a custom software solution for the clinic using OAuth API-integration to protect the participants’ privacy while also enabling fully integrated patient feedback and data collection platform. This will allow for the large scale and reduce data collection and interpretation variables for dose measurement and patient feedback. UK clinics predominantly focus on CBPMHs as a treatment for: multiple sclerosis, chemotherapy-induced nausea, treatment-resistant childhood epilepsy, chronic pain, and weight loss associated with HIV/AIDS. According to Prohibition Partners, up to 1% of the UK population could be medical cannabis patients by 2028. The total legal cannabis market is anticipated to reach $3 billion by 2024, with the medicinal cannabis market taking up $1.3 billion of that estimate (https://ibn.fm/0UaVu). The European cannabis investment sector has turned its attention to the UK market with London playing host to the annual Cannabis Europa conference and seeing the arrival of numerous consultancies, market research, and cannabis-focused finance groups. “We are pleased to bring RYAH’s IoT device and integrated data solutions to the United Kingdom, providing a new level of session accuracy, patient feedback consistency, and data integrity to the clinical framework in plant-based medicine research. We continue to evolve our product and software solutions to help clinicians and researchers unlock breakthroughs in clinical research and analytics,” said Gregory Wagner, CEO of RYAH Group, Inc. For more information, visit the company’s website at www.RYAHGroup.com. NOTE TO INVESTORS: The latest news and updates relating to RYAH Group are available in the company’s newsroom at https://ibn.fm/RYAH